Ceritinib information

Ceritinib
Clinical data
Pronunciation	/səˈrɪtɪnɪb/ sə-RIT-i-nib
Trade names	Zykadia, others
Other names	LDK378
AHFS/Drugs.com	Multum Consumer Information
Routes of; administration	By mouth
ATC code	L01ED02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Bioavailability	Not determined
Protein binding	97%
Metabolism	CYP3A
Elimination half-life	41 hours
Excretion	Feces (92.3%), urine (1.3%)
Identifiers
	IUPAC name 5-Chloro-N2-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine;
CAS Number	1032900-25-6;
PubChem CID	57379345;
DrugBank	DB09063;
ChemSpider	29315053;
UNII	K418KG2GET;
KEGG	D10551;
ChEBI	CHEBI:78432;
ChEMBL	ChEMBL2403108;
PDB ligand	4MK (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID10725373 ;
ECHA InfoCard	100.241.919
Chemical and physical data
Formula	C28H36ClN5O3S
Molar mass	558.14 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl;
	InChI InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34); Key:VERWOWGGCGHDQE-UHFFFAOYSA-N;

Ceritinib (INN,^[4] trade name Zykadia /zaɪˈkeɪdiːə/ zy-KAY-dee-ə) is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC).^[5] It was developed by Novartis and received FDA approval for use in April 2014.^[5]

^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ "Zykadia (ceritinib) Capsules, for Oral Use. Full Prescribing Information" (PDF). Novartis Pharmaceuticals Corporation. Retrieved 14 February 2017.
^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 71" (PDF). World Health Organization. 2014. p. 79. Retrieved 14 February 2017.
^ ^a ^b "FDA Approves Ceritinib for ALK-Positive Lung Cancer". Medscape. April 29, 2014.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

[2] "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

[PI-3] "Zykadia (ceritinib) Capsules, for Oral Use. Full Prescribing Information" (PDF). Novartis Pharmaceuticals Corporation. Retrieved 14 February 2017.

[INN-4] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 71" (PDF). World Health Organization. 2014. p. 79. Retrieved 14 February 2017.

[Medscape-5] "FDA Approves Ceritinib for ALK-Positive Lung Cancer". Medscape. April 29, 2014.

Ceritinib information

and 17 Related for: Ceritinib information

Ceritinib

LDK

ALK inhibitor

Lung cancer

ALK positive lung cancer

ROS1

Anaplastic lymphoma kinase

Mosunetuzumab

List of drugs granted breakthrough therapy designation

Karin Briner

Elranatamab

CYP2C9

CYP3A4

Adenocarcinoma of the lung

ATC code L01

Targeted molecular therapy for neuroblastoma

Inflammatory myofibroblastic tumour

Clinical data

Pronunciation	/səˈrɪtɪnɪb/ sə-RIT-i-nib
Trade names	Zykadia, others
Other names	LDK378
AHFS/Drugs.com	Multum Consumer Information
Routes of administration	By mouth
ATC code	L01ED02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)^[1] CA: ℞-only^[2] US: ℞-only
Pharmacokinetic data
Bioavailability	Not determined
Protein binding	97%
Metabolism	CYP3A
Elimination half-life	41 hours
Excretion	Feces (92.3%), urine (1.3%)^[3]
Identifiers
IUPAC name 5-Chloro-N²-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N⁴-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine
CAS Number	1032900-25-6
PubChem CID	57379345
DrugBank	DB09063
ChemSpider	29315053
UNII	K418KG2GET
KEGG	D10551
ChEBI	CHEBI:78432
ChEMBL	ChEMBL2403108
PDB ligand	4MK (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID10725373
ECHA InfoCard	100.241.919
Chemical and physical data
Formula	C₂₈H₃₆ClN₅O₃S
Molar mass	558.14 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
InChI InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) Key:VERWOWGGCGHDQE-UHFFFAOYSA-N